PurpleDaisy Logo
PurpleDaisyResources
BiomarkersReference MatrixLab PanelsCalculatorsCompareGuidesBlog
Download on the App Store
BiomarkersReference MatrixLab PanelsCalculatorsCompareGuidesBlog

Biomarker Encyclopedia

500+ Items
Master Catalogs
  • All 500+ Biomarkers Directory
  • Longevity Reference MatrixPDF
Categories (500+ Markers)
  • Cardiovascular & Lipidology
  • Metabolic & Glycemic Control
  • Renal Physiology & Electrolytes
  • Hepatic & Biliary Function
  • Hematology & CBC
  • Iron Metabolism & Oxygen Transport
  • Endocrinology & Hormones
  • Micronutrients & Vitamins
  • Immunology & Longevity Clocks
Download Meridian on the App Store
Home/Biomarkers/Endocrinology & Hormones/%fPSA
Endocrinology & HormonesUnbound Prostate-Specific Antigen Ratio

Free PSA Percentage (%fPSA)

Mathematical percentage of circulating uncomplexed free PSA relative to total PSA in the diagnostic 'gray zone' (4.0 to 10.0 ng/mL).

Standard Range>25% (when Total PSA is 4.0 - 10.0 ng/mL)
Optimal Longevity>25% (low risk of prostate cancer)
Measurement Unit%
Organ SystemUnbound Prostate-Specific Antigen Ratio
Routine Panels:Prostate Reflex PanelBiopsy Decision Profile

Standard vs. Optimal Reference Ranges%

Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.

Interactive Range Analyzer
Unit: %
%
Presets:
2 %Optimal Zone Target68 %
Optimal Longevity Zone(37.5 %)

Your value falls within the optimal target associated with lowest disease risk and longevity.

Standard Reference Interval

>25% (when Total PSA is 4.0 - 10.0 ng/mL)

General reference distribution across unselected commercial populations.

Optimal Longevity Target

>25% (low risk of prostate cancer)

Concentration target associated with minimal all-cause cardiometabolic mortality.

Molecular Mechanism & Clinical Purpose

Prostate cancer tissue predominantly secretes PSA complexed to alpha-1-antichymotrypsin, while benign BPH tissue releases more free unbound PSA.

Differential Diagnosis

Elevated Levels (%fPSA High)

  • •Benign Prostatic Hyperplasia (BPH, high free fraction >25%)

Low Levels (%fPSA Low)

  • •High risk of prostate adenocarcinoma (%fPSA <10%)
  • •Active high-grade prostatic malignancy

Technical Reference & Deep Dive

Biochemistry & Enzymatic Pathways
At the molecular level, Free PSA Percentage (%fPSA) plays an essential physiological role in unbound prostate-specific antigen ratio. Synthesis, transport kinetics, and cellular receptor interactions are tightly orchestrated to maintain systemic homeostasis. Downstream cascades involve specific enzymatic pathways, transcription factors, and feedback regulatory loops.
Longevity Risk Architecture & Epidemiology
Percentage >25% indicates high likelihood of benign BPH, whereas %fPSA <10% confers a high risk of prostate cancer, mandating MRI/biopsy.
Pre-Analytical Caveats & Diagnostic Workup

Pre-Analytical Considerations:

Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.

Reflexive Testing Protocol:

  • Confirmatory testing and secondary biomarker quantification for %fPSA
  • Targeted organ system imaging or functional dynamic testing related to unbound prostate-specific antigen ratio
  • Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
  • [1]Clinical Reference and Molecular Physiology of Free PSA Percentage - The New England Journal of Medicine (2021). PMID: 34090124
  • [2]%fPSA Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35322901
Common Panels:Prostate Reflex PanelBiopsy Decision Profile
View All Panels

Associated Longevity Guides & Clinical Calculators

Medicine 3.0

Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Free PSA Percentage (%fPSA) into overall healthspan optimization.

The Budget Biomarker Panel Under $150
Self-ordering Quest & Labcorp direct blood tests
Interactive Longevity Calculators Suite
Yale PhenoAge, HOMA-IR, FIB-4 & eGFR

Related Endocrinology & Hormones Biomarkers

High-Sensitivity C-Reactive Protein
hs-CRP · < 0.5 mg/L
Serum Creatinine
Cr · 0.8 - 1.1 mg/dL (stable across time)
Apolipoprotein B
ApoB · < 60 mg/dL (or < 50 mg/dL in high-risk phenotypes)
PreviousTotal Prostate-Specific Antigen (Total PSA)Endocrinology & HormonesNextProstate Health Index (phi)Endocrinology & Hormones